NCT05346809View on ClinicalTrials.gov

Isatuximab During Stem Cell Collection and Transplant in Patients With Multiple Myeloma and Lymphoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

March 31, 2023

Primary Completion Date

September 30, 2026

Study Completion Date

September 30, 2026

Conditions
LymphomaMultiple MyelomaNon-Hodgkin LymphomaRelapsed Hodgkin's Disease, Adult
Interventions
DRUG

Isatuximab

Isatuximab in IV form 10 mg/kg doses

OTHER

Standard Procedures

Standard procedures (standard of care) for transplant

Trial Locations (2)

10032

RECRUITING

Columbia University, New York

48201

RECRUITING

Karmanos Cancer Institute, Detroit

All Listed Sponsors
collaborator

Genzyme, a Sanofi Company

INDUSTRY

lead

Divaya Bhutani

OTHER